

Company Announcements Office  
ASX Compliance Pty Limited  
Level 40 Central Park  
152-158 St George's Terrace  
PERTH WA 6000

15 November 2021

### Response to ASX Price Query

We refer to your letter dated 15 November 2021 regarding the share price and volume of HeraMED Limited (**HMD** or the **Company**), and respond to your questions as follows:

1. Is HMD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

**Response:** The Company is not aware of any information concerning it that has not been previously announced to the market, which, if known, could be an explanation for recent trading in the securities of HMD. We refer to the recent quarterly report announced to the market on 29 October 2021 which indicated positive interim results for the HeraCARE paid pilot with US-based Obstetrix Medical Group (part of Mednax Inc.), with a second site confirmed for Atlanta, Georgia. The Company is also aware that Mednax Inc. has updated its website to include information concerning its relationship with HMD.

2. If the answer to question 1 is yes:

- (a) Is HMD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in HMD's securities would suggest to ASX that such information may have ceased to be confidential and therefore HMD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation
- (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
- (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

**Response:** Not applicable.

3. If the answer to question 1 is "no", is there any other explanation that HMD may have for the recent trading in its securities?

**Response:** The Company is not aware of any other explanation for the price change in the securities of the Company, other than as mentioned in the response to Question 1 above.

4. Please confirm that HMD is complying with the Listing Rules and, in particular, Listing Rule 3.1.

**Response:** HMD confirms that the Company has been advised of a technical breach of Listing Rule 7.1 relating to the interest component of the convertible notes and the required placement holiday has been served and that a more fulsome announcement will be released in due course. Other than this, the Company is in compliance with the ASX Listing Rules, in particular, Listing Rule 3.1.

5. Please confirm that HMD's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of HMD with delegated authority from the board to respond to ASX on disclosure matters.

**Response:** The Company confirms that HMD's responses to the questions above have been authorized and approved in accordance with its published Continuous Disclosure Policy.

**Released on authority of the Board by:**

Ron Weinberger  
Non-Executive Chairman

**Investor Enquiries:**

Pac Partners  
Tim Chapman  
0419 897 062  
[tchapman@pacpartners.com.au](mailto:tchapman@pacpartners.com.au)



15 November 2021

Reference: 42579

Mr Jonathan Hart  
Company Secretary  
HeraMED Limited

By email

Dear Mr Hart

### **HeraMED Limited ('HMD'): Price and Volume Query**

ASX refers to the following:

- A. The change in the price of HMD's securities from a low of \$0.195 on 11 November 2021 to an intraday high of \$0.32 today.
- B. The significant increase in the volume of HMD's securities traded from 11 November 2021 to 15 November 2021.

### **Request for information**

In light of this, ASX asks HMD to respond separately to each of the following questions and requests for information:

1. Is HMD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is HMD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in HMD's securities would suggest to ASX that such information may have ceased to be confidential and therefore HMD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that HMD may have for the recent trading in its securities?
4. Please confirm that HMD is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that HMD's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of HMD with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AWST Monday, 15 November 2021**. You should note that if the

---

information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, HMD's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require HMD to request a trading halt immediately.

Your response should be sent to me by e-mail at [ListingsCompliancePerth@asx.com.au](mailto:ListingsCompliancePerth@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in HMD's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in HMD's securities under Listing Rule 17.3.

### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to HMD's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that HMD's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Release of correspondence between ASX and entity**

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

### **Questions**

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours faithfully

---

**Damian Dinelli**  
Adviser, Listings Compliance (Perth)